Zobrazeno 1 - 10
of 136
pro vyhledávání: '"Zeenat, Safdar"'
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 3, Pp n/a-n/a (2024)
Abstract Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH
Externí odkaz:
https://doaj.org/article/48df7642be5540f6b68bec7752a20a82
Autor:
Chidinma Ejikeme, Zeenat Safdar
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
Pulmonary hypertension (PH) is a complex cardiopulmonary disorder impacting the lung vasculature, resulting in increased pulmonary vascular resistance that leads to right ventricular dysfunction. Pulmonary hypertension comprises of 5 groups (PH group
Externí odkaz:
https://doaj.org/article/a1d7731a802d48a49ddf37ba54b360f2
Autor:
Nick H. Kim, Kelly M. Chin, Vallerie V. McLaughlin, Hilary DuBrock, Ricardo Restrepo-Jaramillo, Zeenat Safdar, Gwen MacDonald, Nicolas Martin, Daniel Rosenberg, Maria Solonets, Richard Channick
Publikováno v:
Pulmonary Therapy, Vol 10, Iss 1, Pp 85-107 (2024)
Abstract Introduction Portopulmonary hypertension (PoPH) carries a worse prognosis than other forms of pulmonary arterial hypertension (PAH). Data regarding use of PAH-specific therapies in patients with PoPH are sparse as they are usually excluded f
Externí odkaz:
https://doaj.org/article/d2d527f021da4bc98cd27bae7d4bdc4e
Autor:
Madeline Franke, Zeenat Safdar
Publikováno v:
Case Reports in Pulmonology, Vol 2024 (2024)
A 67-year-old woman with pulmonary hypertension (PH) presented with a 1-day history of worsening shortness of breath and pleuritic chest pain and was found to have a troponin T level of 3755 ng/L (ref. range 0–19 ng/L). An initial diagnostic workup
Externí odkaz:
https://doaj.org/article/fd432cf21fcf4e1885543d26084b9179
Autor:
Peifeng Ruan, Jamie L Todd, Hongyu Zhao, Yi Liu, Richard Vinisko, Julia F. Soellner, Ramona Schmid, Robert J. Kaner, Tracy R. Luckhardt, Megan L. Neely, Imre Noth, Mary Porteous, Rishi Raj, Zeenat Safdar, Mary E Strek, Christian Hesslinger, Scott M. Palmer, Thomas B. Leonard, Margaret L. Salisbury
Publikováno v:
Respiratory Research, Vol 24, Iss 1, Pp 1-12 (2023)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix in the pulmonary interstitium and progressive functional decline. We hypothesized that integration of multi-omics data would identify
Externí odkaz:
https://doaj.org/article/54fbde245d2043679df55023d84fe8fb
Autor:
Zeenat Safdar, Eunah Cho
Publikováno v:
Pulmonary Circulation, Vol 11, Iss 4, Pp 1-11 (2021)
Spironolactone, a common diuretic used in the treatment of pulmonary arterial hypertension (PAH), improves cardiopulmonary hemodynamics by attenuating the adverse effects of hyperaldosteronism on endothelin type‐B receptor function within pulmonary
Externí odkaz:
https://doaj.org/article/feae43b6f1f849f2a33c67f2dc06260f
Autor:
Franck F. Rahaghi, Vijay P. Balasubramanian, Robert C. Bourge, Charles D. Burger, Murali M. Chakinala, Michael S. Eggert, Jean M. Elwing, Jeremy Feldman, Christopher King, James R. Klinger, Stephen C. Mathai, John Wesley McConnell, Harold I. Palevsky, Ricardo Restrepo‐Jaramillo, Zeenat Safdar, Jeffrey S. Sager, Namita Sood, Roxana Sulica, R. James White, Nicholas S. Hill
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies sugge
Externí odkaz:
https://doaj.org/article/9f5b66c79cd442eda20ab75c66cf4ff1
Autor:
Franck F. Rahaghi, Zeenat Safdar, Anne Whitney Brown, Joao A. de Andrade, Kevin R. Flaherty, Robert J. Kaner, Christopher S. King, Maria L. Padilla, Imre Noth, Mary Beth Scholand, Adrian Shifren, Steven D. Nathan
Publikováno v:
BMC Pulmonary Medicine, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. Due to a l
Externí odkaz:
https://doaj.org/article/d0b1eef6d42344f291d481150205b102
Autor:
Vijay P. Balasubramanian, Zeenat Safdar, Margaret R. Sketch, Meredith Broderick, Andrew C. Nelsen, Dasom Lee, Lana Melendres‐Groves
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 1, Pp n/a-n/a (2022)
Abstract Real‐world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment, is not always consistent with prescribing information or randomized trials and h
Externí odkaz:
https://doaj.org/article/7954ad2ee75d4d73a75c1d5df5653ef7
Autor:
Joao A. de Andrade, Megan L. Neely, Anne S. Hellkamp, Daniel A. Culver, Hyun J. Kim, Timothy Liesching, Leonard J. Lobo, Murali Ramaswamy, Zeenat Safdar, Shaun Bender, Craig S. Conoscenti, Thomas B. Leonard, Scott M. Palmer, Laurie D. Snyder
Publikováno v:
Clinical Therapeutics. 45:306-315
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::601cb04bffac9aa2ed24212b6ccd28d6
https://doi.org/10.1016/j.clinthera.2023.03.003
https://doi.org/10.1016/j.clinthera.2023.03.003